{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:40:50Z","timestamp":1788273650924,"version":"build-2803163510"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"\n Importance<\/jats:title>\n There are no effective medications for treating dependence on cannabis.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the safety and efficacy of nabiximols in the treatment of patients with cannabis dependence.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This parallel double-blind randomized clinical trial comparing nabiximols with placebo in a 12-week, multisite outpatient study recruited participants from February 3, 2016, to June 14, 2017, at 4 outpatient specialist alcohol and drug treatment services in New South Wales, Australia. Participants had cannabis dependence (as defined by the\n International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n ) and were seeking treatment, were nonresponsive to prior treatment attempts, were 18 to 64 years of age, had no other substance use disorder, had no severe medical or psychiatric conditions, were not pregnant, were not mandated by a court to undergo treatment, and provided informed consent. Results for primary efficacy measures and all secondary outcomes were obtained using a modified intention-to-treat data set.\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants received 12-week treatment involving weekly clinical reviews, structured counseling, and flexible medication doses\u2014up to 32 sprays daily (tetrahydrocannabinol, 86.4 mg, and cannabidiol, 80 mg), dispensed weekly.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcome was self-reported number of days using illicit cannabis during the 12-week period. Other outcomes included alternate cannabis use parameters (periods of abstinence, withdrawal, cravings, and problems), safety parameters (adverse events and aberrant medication use), health status, other substance use, and treatment retention.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 128 participants (30 women and 98 men; mean [SD] age, 35.0 [10.9] years) were randomized and received at least 1 dose of study medication. Participants had used a mean (SD) of 2.3 (2.1) g of cannabis on a mean (SD) of 25.7 (4.5) days in the past 28 days. Treatment retention was comparable for the 2 groups (placebo, 30 of 67 participants [44.8%]; nabiximols, 30 of 61 participants [49.2%]), and both groups used similar mean (SD) doses (placebo, 18.5 [9.5] sprays daily; nabiximols, 17.6 [9.5] sprays daily, equivalent to a mean [SD] of 47.5 [25.7] mg of tetrahydrocannabinol and 44.0 [23.8] mg of cannabidiol). For the primary end point, the placebo group reported significantly more days using cannabis during the 12 weeks (mean [SD], 53.1 [33.0] days) than the nabiximols group (mean [SD], 35.0 [32.4] days; estimated difference, 18.6 days; 95% CI, 3.5-33.7 days;\n P<\/jats:italic>\n \u2009=\u2009.02). Both groups showed comparable improvements in health status, with no substantial changes in other substance use. Medication was well tolerated with few adverse events.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This study demonstrates that cannabinoid agonist treatment, in this case using nabiximols, in combination with psychosocial interventions is a safe approach for reducing cannabis use among individuals with cannabis dependence who are seeking treatment.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n anzctr.org.au<\/jats:ext-link>\n Identifier:\n ACTRN12616000103460<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamainternmed.2019.1993","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T11:05:22Z","timestamp":1563188722000},"page":"1242","source":"Crossref","is-referenced-by-count":93,"title":["Nabiximols for the Treatment of Cannabis Dependence"],"prefix":"10.1001","volume":"179","author":[{"given":"Nicholas","family":"Lintzeris","sequence":"first","affiliation":[{"name":"Drug and Alcohol Services, South East Sydney Local Health District, Sydney, New South Wales, Australia"},{"name":"Discipline Addiction Medicine, Faculty Medicine and Health, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services, South East Sydney Local Health District, Sydney, New South Wales, Australia"},{"name":"Discipline Addiction Medicine, Faculty Medicine and Health, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llewellyn","family":"Mills","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services, South East Sydney Local Health District, Sydney, New South Wales, Australia"},{"name":"Discipline Addiction Medicine, Faculty Medicine and Health, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Dunlop","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services, Hunter New England Local Health District, Newcastle, New South Wales, Australia"},{"name":"Priority Research Centre for Brain and Mental Health, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Copeland","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"McGregor","sequence":"additional","affiliation":[{"name":"Lambert Initiative Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimondo","family":"Bruno","sequence":"additional","affiliation":[{"name":"School of Psychology, University of Tasmania, Hobart, Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gugusheff","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services, South East Sydney Local Health District, Sydney, New South Wales, Australia"},{"name":"Discipline Addiction Medicine, Faculty Medicine and Health, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nghi","family":"Phung","sequence":"additional","affiliation":[{"name":"Drug Health, Western Sydney Local Health District, Parramatta, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Montebello","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services, South East Sydney Local Health District, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Chan","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services, South East Sydney Local Health District, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Kirby","sequence":"additional","affiliation":[{"name":"National Health and Medical Research Council, Clinical Trials Centre, Faculty of Medicine and Public Health, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hall","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services, Hunter New England Local Health District, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Jefferies","sequence":"additional","affiliation":[{"name":"Drug Health, Western Sydney Local Health District, Parramatta, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Luksza","sequence":"additional","affiliation":[{"name":"Drug Health, Western Sydney Local Health District, Parramatta, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Shanahan","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kevin","sequence":"additional","affiliation":[{"name":"Drug and Alcohol Services, Hunter New England Local Health District, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Allsop","sequence":"additional","affiliation":[{"name":"Lambert Initiative Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Agonist Replacement for Cannabis Dependence (ARCD) study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9698","key":"ioi190043r4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(09)61037-0","article-title":"Adverse health effects of non-medical cannabis use.","volume":"374","author":"Hall","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"ioi190043r7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"ioi190043r8","first-page":"43","article-title":"A double blind, randomised, placebo controlled trial of lithium carbonate for the management of cannabis withdrawal: paper 220.","volume":"32","author":"Johnston","year":"2013","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"ioi190043r9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005336.pub4","article-title":"Psychosocial interventions for cannabis use disorder.","author":"Gates","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ioi190043r10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.psc.2012.03.003","article-title":"State of the art treatments for cannabis dependence.","volume":"35","author":"Danovitch","year":"2012","journal-title":"Psychiatr Clin North Am"},{"issue":"7","key":"ioi190043r11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2165\/00023210-200923070-00001","article-title":"Pharmacotherapy for cannabis dependence: how close are we?","volume":"23","author":"Vandrey","year":"2009","journal-title":"CNS Drugs"},{"issue":"8","key":"ioi190043r12","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/add.12456","article-title":"Would legalizing illicit opioids reduce overdose fatalities? implications from a natural experiment.","volume":"109","author":"Darke","year":"2014","journal-title":"Addiction"},{"issue":"1","key":"ioi190043r13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00213-007-1020-8","article-title":"Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.","volume":"197","author":"Haney","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"ioi190043r14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/clpt.1992.100","article-title":"Characterization of the absorption phase of marijuana smoking.","volume":"52","author":"Huestis","year":"1992","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"ioi190043r15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1373\/clinchem.2010.152439","article-title":"Plasma cannabinoid pharmacokinetics following controlled oral ?9-tetrahydrocannabinol and oromucosal cannabis extract administration.","volume":"57","author":"Karschner","year":"2011","journal-title":"Clin Chem"},{"issue":"1-3","key":"ioi190043r16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.","volume":"116","author":"Levin","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"ioi190043r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190768","article-title":"Nabiximols combined with motivational enhancement\/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial.","volume":"13","author":"Trigo","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"ioi190043r18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12888-018-1682-2","article-title":"Randomised controlled trial (RCT) of cannabinoid replacement therapy (nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.","volume":"18","author":"Bhardwaj","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"1","key":"ioi190043r22","doi-asserted-by":"publisher","first-page":"10154","DOI":"10.1038\/s41598-018-28127-0","article-title":"Composition and use of cannabis extracts for childhood epilepsy in the Australian community.","volume":"8","author":"Suraev","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"ioi190043r23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11419-016-0330-0","article-title":"Urinary cannabinoid levels during nabiximols (Sativex)-medicated inpatient cannabis withdrawal.","volume":"35","author":"Kevin","year":"2017","journal-title":"Forensic Toxicol"},{"issue":"3","key":"ioi190043r24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"ioi190043r25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugalcdep.2015.11.026","article-title":"Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: the Opioid-Related Behaviours In Treatment (ORBIT) scale.","volume":"159","author":"Larance","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"1-2","key":"ioi190043r26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.drugalcdep.2011.06.003","article-title":"The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress.","volume":"119","author":"Allsop","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"ioi190043r27","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1046\/j.1360-0443.2001.967102312.x","article-title":"Marijuana Craving Questionnaire: development and initial validation of a self-report instrument.","volume":"96","author":"Heishman","year":"2001","journal-title":"Addiction"},{"issue":"3","key":"ioi190043r28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.drugalcdep.2005.04.009","article-title":"The Cannabis Problems Questionnaire: factor structure, reliability, and validity.","volume":"80","author":"Copeland","year":"2005","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"ioi190043r29","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/add.1993.88.issue-6","article-title":"Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption\u2014II.","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"issue":"9","key":"ioi190043r30","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/add.1991.86.issue-9","article-title":"The Fagerstr\u00f6m Test for Nicotine Dependence: a revision of the Fagerstr\u00f6m Tolerance Questionnaire.","volume":"86","author":"Heatherton","year":"1991","journal-title":"Br J Addict"},{"issue":"6","key":"ioi190043r31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"5","key":"ioi190043r32","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/add.1992.87.issue-5","article-title":"Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index.","volume":"87","author":"Darke","year":"1992","journal-title":"Br J Addict"},{"issue":"1","key":"ioi190043r33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"ioi190043r34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.drugalcdep.2018.03.017","article-title":"Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.","volume":"187","author":"Baker","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"ioi190043r36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4.","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"issue":"3","key":"ioi190043r39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"mice: Multivariate imputation by chained equations in R.","volume":"45","author":"Van Buuren","year":"2011","journal-title":"J Stat Softw"},{"issue":"5","key":"ioi190043r40","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/02791072.2014.921743","article-title":"Patient perspectives on buprenorphine\/naloxone: a qualitative study of retention during the Starting Treatment With Agonist Replacement Therapies (START) Study.","volume":"46","author":"Teruya","year":"2014","journal-title":"J Psychoactive Drugs"},{"issue":"9","key":"ioi190043r41","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/npp.2010.58","article-title":"Cannabidiol attenuates the appetitive effects of ? 9-tetrahydrocannabinol in humans smoking their chosen cannabis.","volume":"35","author":"Morgan","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"ioi190043r42","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/jcpt.12018","article-title":"Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report.","volume":"38","author":"Crippa","year":"2013","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"ioi190043r43","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.biopsych.2006.08.027","article-title":"Dorsolateral prefrontal cortex N-acetylaspartate\/total creatine (NAA\/tCr) loss in male recreational cannabis users.","volume":"61","author":"Hermann","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"32","key":"ioi190043r44","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.2174\/138161212802884825","article-title":"Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review.","volume":"18","author":"Hermann","year":"2012","journal-title":"Curr Pharm Des"},{"key":"ioi190043r1","doi-asserted-by":"crossref","DOI":"10.18356\/d30739c2-en","volume-title":"World Drug Report 2013","author":"UN Office on Drugs and Crime","year":"2013"},{"key":"ioi190043r2","doi-asserted-by":"crossref","DOI":"10.18356\/b07f5d3f-en","volume-title":"World Drug Report 2015","author":"UN Office on Drugs and Crime","year":"2015"},{"key":"ioi190043r3","volume-title":"2016 National Drug Strategy Household Survey: Preliminary Findings","author":"Australian Institute of Health and Welfare","year":"2017"},{"key":"ioi190043r5","volume-title":"The Health and Social Effects of Nonmedical Cannabis Use","author":"World Health Organization","year":"2016"},{"key":"ioi190043r6","volume-title":"Cannabis Dependence: Its Nature, Consequences, and Treatment","author":"Roffman","year":"2006"},{"key":"ioi190043r19","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)","author":"World Health Organization","year":"2005","edition":"2nd ed."},{"key":"ioi190043r20","volume-title":"Marijuana Brief Intervention: An SBIRT Approach","author":"Copeland","year":"2017"},{"key":"ioi190043r21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4612-0357-5_3","volume-title":"Measuring Alcohol Consumption: Psychosocial and Biochemical Methods","author":"Sobell","year":"1992"},{"key":"ioi190043r35","year":"2016"},{"key":"ioi190043r38","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2013"},{"key":"ioi190043r37","unstructured":"Wickham? H. tidyverse: Easily install and load the \u2019tidyverse.\u2019 R package version 1.2.1. https:\/\/cran.r-project.org\/web\/packages\/tidyverse\/index.html. Accessed March 12, 2018."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2737918\/jamainternal_lintzeris_2019_oi_190043_1696359120.84903.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T19:47:53Z","timestamp":1721504873000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2737918"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2019.1993","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736199731.793563658","asserted-by":"object"}]},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}